Last reviewed · How we verify
entecavir, lamivudine
Entecavir and lamivudine are nucleoside reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.
Entecavir and lamivudine are nucleoside reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.
At a glance
| Generic name | entecavir, lamivudine |
|---|---|
| Also known as | Entecavir:baraclude, Lamivudine: zeffix |
| Sponsor | Asan Medical Center |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are nucleoside analogues that get incorporated into the growing viral DNA chain during HBV replication, causing chain termination and preventing further viral DNA synthesis. Lamivudine was the first-line agent historically, while entecavir is a more potent second-generation inhibitor with a higher genetic barrier to resistance. This combination targets the same enzyme but may provide additive or synergistic antiviral effects.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Lactic acidosis
- Hepatomegaly
- Elevated transaminases
- Headache
- Fatigue
Key clinical trials
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Effects of Antiviral Therapy on Patients With HBV-related HCC
- Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant (PHASE2)
- Extension Study of Carvedilol RCT Study (NA)
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- entecavir, lamivudine CI brief — competitive landscape report
- entecavir, lamivudine updates RSS · CI watch RSS
- Asan Medical Center portfolio CI